News Releases

Date	Title	View
May 14, 2026	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements	PDF Version
March 28, 2026	Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis	PDF Version
March 19, 2026	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements	PDF Version
March 18, 2026	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting	PDF Version
March 2, 2026	Alumis to Present at the Leerink Partners Global Healthcare Conference	PDF Version
February 5, 2026	Alumis to Participate in Upcoming February Investor Conferences	PDF Version
January 9, 2026	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	PDF Version
January 7, 2026	Alumis Announces Pricing of Upsized Public Offering of Common Stock	PDF Version
January 6, 2026	Alumis Announces Proposed Public Offering of Common Stock	PDF Version
January 6, 2026	Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program	PDF Version